Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
All plitidepsin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPlitidepsinPlitidepsin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes       

A Multicentre, Open Label, Randomised, Controlled, Basket, Pragmatic, Phase II, Clinical and Translational Study to Determine the Efficacy and Safety of Plitidepsin Versus Control in Immunocompromised Adult Patients With Symptomatic COVID-19 Requiring Hospital Care

PharmaMar, NCT05705167, NEREIDA, NCT05705167
Dec 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -36% Improvement Relative Risk Mortality, day 30 25% Plitidepsin  NEREIDA  LATE TREATMENT  RCT Is late treatment with plitidepsin beneficial for COVID-19? RCT 37 patients in Belgium Trial underpowered to detect differences c19early.org PharmaMar, NCT05705167, December 2024 Favorsplitidepsin Favorscontrol 0 0.5 1 1.5 2+
RCT 37 hospitalized immunocompromised patients, showing no significant benefit with plitidepsin treatment.
risk of death, 36.4% higher, RR 1.36, p = 1.00, treatment 5 of 22 (22.7%), control 1 of 6 (16.7%).
risk of death, 25.0% lower, RR 0.75, p = 1.00, treatment 3 of 20 (15.0%), control 1 of 5 (20.0%), NNT 20, day 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
PharmaMar et al., 2 Dec 2024, Randomized Controlled Trial, Belgium, preprint, 1 author, trial NCT05705167 (history) (NEREIDA). Contact: clinicaltrials@pharmamar.com.
This PaperPlitidepsinAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit